HOME > TOP STORIES
TOP STORIES
-
BUSINESS Japanese Pricing Rules Don’t Fully Capture Value of New Modalities, “No” to CEA Expansion: Janssen Exec
November 17, 2023
-
REGULATORY Wegovy Lands Reimbursement Listing in Japan 8 Months after Approval
November 16, 2023
-
ORGANIZATION PhRMA Chief Presses Japan to Cut LLP Spending, Shift Funds towards Innovation
November 15, 2023
-
REGULATORY Japan Health Minister Seeks Industry Input for Detailed Discussions on Innovation Ecosystem
November 14, 2023
-
BUSINESS Ajinomoto to Acquire US Gene Therapy CDMO for US$554 Million
November 14, 2023
-
REGULATORY MHLW Proposes New Premium with Easier-than-Sakigake Requirements to Fight Lag, Loss
November 13, 2023
-
REGULATORY Japan Panel Supports Certain Out-of-Pocket Payment for LLP-Generic Price Gap
November 10, 2023
-
ORGANIZATION PhRMA Chair Urges Japan to Maintain On-Patent Drug Prices, Improve Initial Pricing
November 10, 2023
-
BUSINESS Middle East Unrest Threatens Supply of Kaken’s Burn Eschar Remover
November 9, 2023
-
REGULATORY Health Minister Asks 24 Makers to Raise Production of Antitussives, Expectorants; Firms Want Regulatory, Pricing Steps
November 8, 2023
-
REGULATORY Govt to Support Shift to 24-Hour Production for Cough Drugs: Minister
November 8, 2023
-
BUSINESS Eisai CEO Confident of Achieving Leqembi Sales Goal of 10 Billion Yen in FY2023
November 8, 2023
-
BUSINESS Air Pollutant Might Be to Blame for NDMA Formation in Metformin: Towa Paper
November 7, 2023
-
BUSINESS Chugai Offloading Xeloda to Cheplapharm after German Firm Plants Flag in Japan
November 7, 2023
-
REGULATORY Health Minister to Make Direct Request to 24 Makers for Supply Ramp-Up
November 7, 2023
-
REGULATORY Japan PM Advisor Pushes Rethink of LLP Coverage to Reward Innovation, Pricing Debate without Taboos
November 6, 2023
-
REGULATORY Japan OKs New Economic Package; Startup, Pharma Promotion Embraced
November 6, 2023
-
REGULATORY Reward Innovation by Revisiting LLP Copay, Cut Doctor Fees: MOF
November 2, 2023
-
BUSINESS Sumitomo Eyes Return to Core Operating Profit in FY2024, Pruning Roivant Shares
November 1, 2023
-
BUSINESS 301 Employees Apply for Shionogi’s Voluntary Buyout Program
November 1, 2023
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
